07:00 , Oct 2, 2000 |  BC Week In Review  |  Company News

Proteome Sciences management update

Proteome Sciences plc (LSE:PRM), Cobham, U.K.   Business: Diagnostics/Imaging, Drug discovery   Hired: Gerard McGarrity as CEO of PRM's Intronn LLC U.S. gene therapy subsidiary, formerly CSO of Cambridge Genetics Ltd.  ...
07:00 , Sep 27, 2000 |  BC Extra  |  Company News

Proteome subsidiary picks new CEO

Proteome (LSE:PRM) hired Gerard McGarrity as CEO of its U.S. gene therapy subsidiary Intronn (Durham, N.C.). McGarrity was the CSO of Cambridge Genetics....
08:00 , Jan 10, 2000 |  BC Week In Review  |  Company News

Cambridge Drug Discovery Ltd., Cambridge Genetics, Oxford Molecular deal

Cambridge Genetics acquired Cambridge Drug in a stock transaction. Cambridge Genetics also bought OMG's 19.99 percent stake in Cambridge Drug for £650,000 ($1.06 million) in cash and a £1million ($1.64 million) zero coupon loan note...
07:00 , May 17, 1999 |  BC Week In Review  |  Company News

Cambridge Genetics, Mayo Foundation deal

The parties signed a five-year agreement to develop gene-based cancer therapeutics. Cambridge Genetics will provide its viral membrane protein (VMP) engineering technology, which targets delivery of genes to specific cancer cells and promotes cell fusion...
07:00 , May 17, 1999 |  BioCentury  |  Finance

Neuer Markt: Launch and hope

European life science companies showed they can still raise equity capital on the Neuer Markt, as Sanochemia Pharmazeutika (NMarkt:SAC) raised E53.75 million ($57.8 million) and MWG Biotech (NMarkt:NWU) raised E40.5 million ($43.6 million) in their...
08:00 , Jan 11, 1999 |  BioCentury  |  Finance

Getting the pulse racing

Getting the pulse racing While it remains to be seen what sort of bump the biotech market will get with this week's 17th Annual Hambrecht & Quist Healthcare Conference, biotech has jumped out in front...